Non-nucleoside reverse transcriptase inhibitors

US6706706B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Jeffrey O'Meara · Laval, CA
• Bruno Simoneau · Laval, CA
• Christiane Yoakim · Laval, CA
• Robert Deziel · Mount Royal, CA
• William W. Ogilvie · Rosemère, CA

Key dates

• Filing date: Mar 4, 2003
• Grant date: Mar 16, 2004
• Expiry date: Mar 16, 2023

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are compounds of formula I: whereinR2 is H, halogen, (C1-4)alkyl, O(C1-4)alkyl, NH(C1-4alkyl) or N(C1-4alkyl)2;R4 is H or CH3;R5 is H or CH3;R12 is H, halogen, (C1-4)alkyl, CF3, or NO2;R13 is H, (C1-4)alkyl, halogen, OH, or NH2, with the proviso that R12 and R13 are not both H; andR14 is COOR14a wherein R14a is H or (C1-6)alkyl; or R14 is (C2-4)alkenyl-COOR14a wherein R14a is as defined herein; or R14 is (C1-4)alkyl-COOR14a wherein R14a is as defined above;or a salt or a prodrug thereof, useful as inhibitors of HIV reverse transcriptase.